Template:KDRG: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 26: | Line 26: | ||
#[[Sparsentan]] | #[[Sparsentan]] | ||
#[[BRENZAVVY- bexagliflozin]] | #[[BRENZAVVY- bexagliflozin]] | ||
#[[COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)]] | #[[COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)]] | ||
#[[Nirsevimab]] | #[[Nirsevimab]] | ||
| Line 32: | Line 31: | ||
#[[EXXUA]] | #[[EXXUA]] | ||
#[[Somatrogon-ghla]] | #[[Somatrogon-ghla]] | ||
#[[Aprocitentan]] | #[[Aprocitentan]] | ||
#[[WINREVAIR]] | #[[WINREVAIR]] | ||
#[[Xolremdi]] | #[[Xolremdi]] | ||
#[[Rytelo]] | #[[Rytelo]] | ||
#[[Clinical assessment of lower extremity peripheral arterial disease]] | #[[Chronic obstructive pulmonary disease history and symptoms]] New Guidelines 2024 | ||
#[[Chronic renal failure overview]] New Guidelines 2024 | |||
#[[Clinical assessment of lower extremity peripheral arterial disease]] New Guidelines 2024 | |||
Latest revision as of 18:17, 20 August 2024
Kosar Doraghi, M.D.
Current Position
Associate Editor-in-Chief, Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar
Pages Authored/Co-authored/Collaborated
- NEXOBRID
- RELYVRIO
- Deucravacitinib
- Ublituximab-xiiy
- LYTGOBI- futibatinib
- Tapinarof
- Spevigo- spesolimab-sbz
- Vericiguat
- Dasiglucagon
- Ponesimod
- Lasmiditan
- Nirogacestat
- Nedosiran
- Ryzneuta
- Endocarditis overview
- Sparsentan
- BRENZAVVY- bexagliflozin
- COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)
- Nirsevimab
- Xacduro- sulbactam and durlobactam
- EXXUA
- Somatrogon-ghla
- Aprocitentan
- WINREVAIR
- Xolremdi
- Rytelo
- Chronic obstructive pulmonary disease history and symptoms New Guidelines 2024
- Chronic renal failure overview New Guidelines 2024
- Clinical assessment of lower extremity peripheral arterial disease New Guidelines 2024